ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 159 filers reported holding ESPERION THERAPEUTICS INC NE in Q4 2020. The put-call ratio across all filers is 1.82 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,827,045 | +487.5% | 1,864,332 | +733.2% | 0.00% | – |
| Q2 2023 | $311,009 | +4.7% | 223,747 | +19.8% | 0.00% | – |
| Q1 2023 | $297,000 | +12586.9% | 186,795 | -50.3% | 0.00% | – |
| Q4 2022 | $2,341 | -99.9% | 375,846 | -6.2% | 0.00% | – |
| Q3 2022 | $2,686,000 | -52.0% | 400,836 | -54.5% | 0.00% | -100.0% |
| Q2 2022 | $5,600,000 | +60.1% | 880,523 | +16.8% | 0.00% | – |
| Q1 2022 | $3,497,000 | +495.7% | 753,840 | +542.6% | 0.00% | – |
| Q4 2021 | $587,000 | -43.6% | 117,303 | +35.7% | 0.00% | – |
| Q3 2021 | $1,041,000 | -34.4% | 86,455 | +15.2% | 0.00% | – |
| Q2 2021 | $1,588,000 | -54.6% | 75,075 | -39.8% | 0.00% | – |
| Q1 2021 | $3,501,000 | +2.5% | 124,787 | -5.0% | 0.00% | -100.0% |
| Q4 2020 | $3,415,000 | -31.9% | 131,330 | -1.9% | 0.00% | 0.0% |
| Q3 2020 | $5,017,000 | -31.3% | 133,908 | -5.9% | 0.00% | 0.0% |
| Q2 2020 | $7,303,000 | +70.8% | 142,321 | +5.0% | 0.00% | 0.0% |
| Q1 2020 | $4,275,000 | -29.2% | 135,561 | +33.8% | 0.00% | 0.0% |
| Q4 2019 | $6,042,000 | +19.6% | 101,306 | -26.5% | 0.00% | 0.0% |
| Q3 2019 | $5,052,000 | -26.5% | 137,797 | -2.2% | 0.00% | 0.0% |
| Q2 2019 | $6,875,000 | +110.4% | 140,825 | +73.0% | 0.00% | 0.0% |
| Q1 2019 | $3,268,000 | -65.1% | 81,400 | -60.0% | 0.00% | -50.0% |
| Q4 2018 | $9,358,000 | +196.6% | 203,438 | +186.1% | 0.00% | +100.0% |
| Q3 2018 | $3,155,000 | +17.1% | 71,095 | +3.4% | 0.00% | 0.0% |
| Q2 2018 | $2,694,000 | -84.9% | 68,747 | -72.1% | 0.00% | -75.0% |
| Q1 2018 | $17,812,000 | +228.9% | 246,251 | +199.4% | 0.00% | +300.0% |
| Q4 2017 | $5,416,000 | +75.4% | 82,261 | +33.1% | 0.00% | 0.0% |
| Q3 2017 | $3,087,000 | -60.5% | 61,800 | -63.4% | 0.00% | -50.0% |
| Q2 2017 | $7,812,000 | +20.3% | 168,800 | -8.2% | 0.00% | +100.0% |
| Q1 2017 | $6,493,000 | +163.9% | 183,908 | -6.4% | 0.00% | 0.0% |
| Q4 2016 | $2,460,000 | -2.1% | 196,500 | +8.3% | 0.00% | 0.0% |
| Q3 2016 | $2,512,000 | +78.9% | 181,400 | +27.6% | 0.00% | – |
| Q2 2016 | $1,404,000 | -16.8% | 142,161 | +42.4% | 0.00% | – |
| Q1 2016 | $1,687,000 | -30.8% | 99,800 | -8.9% | 0.00% | -100.0% |
| Q4 2015 | $2,438,000 | -49.4% | 109,500 | -46.4% | 0.00% | 0.0% |
| Q3 2015 | $4,821,000 | -51.6% | 204,331 | +89.8% | 0.00% | -50.0% |
| Q1 2015 | $9,970,000 | – | 107,674 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,679,835 | $69,675,000 | 19.39% |
| Endurant Capital Management LP | 207,293 | $5,390,000 | 1.94% |
| Bellevue Group AG | 5,138,451 | $133,599,000 | 1.53% |
| Rhenman & Partners Asset Management AB | 592,225 | $15,398,000 | 1.26% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 1,562,869 | $40,635,000 | 0.93% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 31,434 | $817,000 | 0.62% |
| WASATCH ADVISORS LP | 3,998,010 | $103,949,000 | 0.51% |
| HAMILTON LANE ADVISORS LLC | 46,181 | $1,201,000 | 0.45% |
| Boxer Capital, LLC | 500,000 | $13,000,000 | 0.42% |
| DCF Advisers, LLC | 38,500 | $1,001,000 | 0.41% |